Basal Stimulation Therapy for Adults With Schizophrenia Living in Institutional Care
Tests basal stimulation therapy in adults with schizophrenia who need permanent institutional care.
Plain-language title generated from the registry record
Registry title: Basal Stimulation Therapy in Adults With Schizophrenia Requiring Institutional Care
Key facts
- Where
- Katowice and Rybnik, PolandSee the 2 sites
Where in Poland
- Jerzy Kukuczka Academy of Physical Education in Katowice, PolandKatowice, PolandNo longer taking part
- Clinical Psychiatric Hospital SPZOZ in Rybnik, PolandRybnik, PolandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Jerzy Kukuczka Academy of Physical Education in Katowice
- Trial code
- NCT07769749
- Record updated
- 18 August 2026
- Original description
The aim of the study is to obtain knowledge of the impact of basal stimulation therapy on the health status of adults suffering from schizophrenia and requiring permanent institutional care.Read full original descriptionShow less
The Impact of Basal Stimulation Therapy in Adult Patients With Schizophrenia Requiring Permanent Institutional Care
The aim of the study is to obtain knowledge of the impact of basal stimulation therapy on the health status of adults suffering from schizophrenia and requiring permanent institutional care.
The use of basal stimulation therapy in many European centres for several decades, combined with the limited amount of scientific evidence, justifies undertaking the proposed research. Available evidence indicates reduced anxiety and improved quality of life. No such studies have previously been conducted in institutionalized patients with schizophrenia.
Study inclusion criteria:; women and men aged ≥ 55 years,; consent of the legal guardian/caregiver to participate in the study,; schizophrenia clinically confirmed for at least 5 years, with predominance of negative symptoms,; stable drug therapy (treatment unchanged for at least 3 months); functional ability of everyday life on the Barthel scale below 40 points; The exclusion criteria from the study will be:; lack of consent to participate in the study; pregnancy; general contraindications (acute inflammatory conditions and diseases accompanied by fever, venous thrombosis, unstable arterial hypertension , early condition after contrast-enhanced computed tomography, early condition after lumbar puncture, general serious condition of the patient ); exacerbation of the main disease (acute psychosis, severe anxiety, tendency to active aggression, visual seizures); active cancer; diseases of the nervous system (neuropathies, stroke , damage to the cerebellum, labyrinth) causing altered sensitivity to stimuli; diseases and illnesses of the musculoskeletal system that significantly disturb the body's balance and the mobility of the limbs; pressure ulcers grade IV and V on the Torrance scale.